#### 505197275 11/19/2018

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5244044

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

# **CONVEYING PARTY DATA**

Name	Execution Date
ATSUSHI KUWAHARA	09/21/2018
SUGURU YAMASAKI	09/21/2018
MIYUKI (LEGAL REPRESENTATIVE OF DECEASED INVENTOR YOSHIKI SASAI) SASAI	10/09/2018
MASAYO TAKAHASHI	09/28/2018

# **RECEIVING PARTY DATA**

Name:	SUMITOMO DAINIPPON PHARMA CO., LTD.	
Street Address:	6-8, DOSHO-MACHI 2-CHOME, CHUO-KU	
City:	OSAKA-SHI, OSAKA	
State/Country:	JAPAN	
Postal Code:	541-8524	
Name:	RIKEN	
Street Address:	2-1, HIROSAWA	
City:	WAKO-SHI, SAITAMA	
State/Country:	JAPAN	
Postal Code:	351-0198	
Name:	SUMITOMO CHEMICAL COMPANY, LIMITED	
Street Address:	27-1, SHINKAWA 2-CHOME, CHUO-KU	
City:	TOKYO	
State/Country:	JAPAN	
Postal Code:	104-8260	

# **PROPERTY NUMBERS Total: 1**

Property Type	Number
Application Number:	16095339

# **CORRESPONDENCE DATA**

**Fax Number:** (312)616-5700

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

(312) 616-5600 Phone:

> PATENT REEL: 047541 FRAME: 0658

Email: mgreer@leydig.com
Correspondent Name: JOHN KILYK, JR.

Address Line 1: LEYDIG, VOIT & MAYER, LTD.

Address Line 2: TWO PRUDENTIAL PLAZA, SUITE 4900

Address Line 4: CHICAGO, ILLINOIS 60601-6731

ATTORNEY DOCKET NUMBER: 740921

NAME OF SUBMITTER: JOHN KILYK, JR.

SIGNATURE: /John Kilyk, Jr./

**DATE SIGNED:** 11/19/2018

**Total Attachments: 9** 

source=Assignment#page1.tif

source=Assignment#page2.tif

source=Assignment#page3.tif

source=Assignment#page4.tif

source=Assignment#page5.tif

source=Assignment#page6.tif

source = Assignment # page 7.tif

source=Assignment#page8.tif

source=Assignment#page9.tif

PATENT REEL: 047541 FRAME: 0659

#### ASSIGNMENT

## WHEREAS, I/WE

- (1) Atsushi KUWAHARA of c/o Sumitomo Dainippon Pharma Co., Ltd., Kobe KIMEC Center Building 5th Fl., 5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan,
- (2) Suguru YAMASAKI of c/o Sumitomo Dainippon Pharma Co., Ltd., Kobe KIMEC Center Building 5th Fl., 5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan,
- (3) Miyuki SASAI (Legal Representative of the Deceased Yoshiki SASAI) of 6-4-19, Shinoharanakamachi, Nada-ku, Kobe-shi, Hyogo 657-0066 Japan, and
- (4) Masayo TAKAHASHI of c/o RIKEN, 2-1, Hirosawa, Wako-shi, Saitama 351-0198 Japan,

hereinafter referred to as Assignor, have invented a certain invention entitled:

#### METHOD FOR PRODUCING RETINAL TISSUE

for which invention an application for a U.S. patent was filed on October 19, 2018, under U.S. Application No. 16/095,339, as the U.S. national phase of International Application No. PCT/JP2017/016120, which was filed on April 21, 2017, and

#### WHEREAS,

Sumitomo Dainippon Pharma Co., Ltd. of 6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8524 Japan,

RIKEN of 2-1, Hirosawa, Wako-shi, Saitama 351-0198 Japan, and

SUMITOMO CHEMICAL COMPANY, LIMITED of 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo 104-8260 Japan,

hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

**Now, Therefore**, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility

Page 1 of 3

model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, the patents that may issue thereon, and the patents as may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reexaminations, inter partes reviews, post-grant reviews, and oppositions),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date	21 Sep 2018	Atsushi Kuwahara
17440		Assignor: Atsushi KUWAHARA
Date	21 Sep 2018	Sugurn Yamasaki
Date	Witness: Suguru YAMASAKI	
Date	21 Sep 2018	Tatsuya Kamei
	Tatsuya Kamei Witness: Jotsuya Hamei	

Page 2 of 3

Date 21 Sep 2018	Suguru Yamasaki
	Assignor: Suguru YAMASAKI
Date 21 Sep 2018	Atsushi Kuwahara
	Witness: Atsusi Kuwahara
Date 21 Sep 2018	Tatsuya Kamei Witness: Tatsuya Kamei
•	Witness: Tatsuya Kainei
	2001 2003 FT 20 100 100 AND
Date	Assignor: Miyuki SASAI
	Legal Representative of the Deceased
	Yoshiki SASAI
D /	
Date	Witness:
Date	Witness:
	TY TELEVISION
-	
Date	
Date	Assignor: Masayo TAKAHASHI
Data	
Date	Witness:
Date	Witness:

Page 3 of 3

#### ASSIGNMENT

### WHEREAS, I/WE

- (1) Atsushi KUWAHARA of c/o Sumitomo Dainippon Pharma Co., Ltd., Kobe KIMEC Center Building 5th Fl., 5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan,
- (2) Suguru YAMASAKI of c/o Sumitomo Dainippon Pharma Co., Ltd., Kobe KIMEC Center Building 5th Fl., 5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan,
- (3) Miyuki SASAI (Legal Representative of the Deceased Yoshiki SASAI) of 6-4-19, Shinoharanakamachi, Nada-ku, Kobe-shi, Hyogo 657-0066 Japan, and
- (4) Masayo TAKAHASHI of c/o RIKEN, 2-1, Hirosawa, Wako-shi, Saitama 351-0198 Japan

hereinafter referred to as Assignor, have invented a certain invention entitled:

#### METHOD FOR PRODUCING RETINAL TISSUE

for which invention an application for a U.S. patent was filed on October 19, 2018, under U.S. Application No. 16/095,339, as the U.S. national phase of International Application No. PCT/JP2017/016120, which was filed on April 21, 2017, and

# WHEREAS,

Sumitomo Dainippon Pharma Co., Ltd. of 6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8524 Japan,

RIKEN of 2-1, Hirosawa, Wako-shi, Saitama 351-0198 Japan, and

SUMITOMO CHEMICAL COMPANY, LIMITED of 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo 104-8260 Japan,

hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

**Now, Therefore**, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility

Page 1 of 3

model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, the patents that may issue thereon, and the patents as may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reviews, post-grant reviews, and oppositions),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date	Assignor: Atsushi KUWAHARA
Date	Witness:
Date	Witness:

Page 2 of 3

Date	Assignor: Suguru YAMASAKI
Date	Witness:
Date	Witness:
220000	
Date <u>Oct. 9, 2018</u>	Assignor: Miyuki SASAI  Legal Representative of the Deceased  Yoshiki SASAI
Date Oct. 9, 2018	Witness: Tatsuya Seki
Date <u>Oct. 9.2018</u>	Witness: Hiroshi Fujinoto
Date	Assignor: Masayo TAKAHASHI
Date	Witness:
Date	Witness:

Page 3 of 3

#### ASSIGNMENT

# WHEREAS, I/WE

- (1) Atsushi KUWAHARA of c/o Sumitomo Dainippon Pharma Co., Ltd., Kobe KIMEC Center Building 5th Fl., 5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan,
- (2) Suguru YAMASAKI of c/o Sumitomo Dainippon Pharma Co., Ltd., Kobe KIMEC Center Building 5th Fl., 5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe-shi, Hyogo 650-0047 Japan,
- (3) Miyuki SASAI (Legal Representative of the Deceased Yoshiki SASAI) of 6-4-19, Shinoharanakamachi, Nada-ku, Kobe-shi, Hyogo 657-0066 Japan, and
- (4) Masayo TAKAHASHI of c/o RIKEN, 2-1, Hirosawa, Wako-shi, Saitama 351-0198 Japan

hereinafter referred to as Assignor, have invented a certain invention entitled:

#### METHOD FOR PRODUCING RETINAL TISSUE

for which invention an application for a U.S. patent was filed on October 19, 2018, under U.S. Application No. 16/095,339, as the U.S. national phase of International Application No. PCT/JP2017/016120, which was filed on April 21, 2017, and

#### WHEREAS.

Sumitomo Dainippon Pharma Co., Ltd. of 6-8, Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8524 Japan,

RIKEN of 2-1, Hirosawa, Wako-shi, Saitama 351-0198 Japan, and

SUMITOMO CHEMICAL COMPANY, LIMITED of 27-1, Shinkawa 2-chome, Chuo-ku, Tokyo 104-8260 Japan,

hereinafter referred to as Assignee, is desirous of acquiring the entire right, title, and interest in, to, and under the invention described in the patent application, including the entire priority right derived from the application,

Now, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged,

Assignor assigns and transfers to Assignee and Assignee's legal representatives, successors, and assigns the entire right, title, and interest in, to, and under the invention, the referenced patent application, other such applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, national and regional phase applications, petty patent applications, and utility

Page 1 of 3

model applications) that may be filed in the U.S. and/or any country foreign to the U.S. on the invention, the patents that may issue thereon, and the patents as may be modified as the result of applicable procedures (e.g., supplemental examinations, ex parte reexaminations, inter partes reviews, post-grant reviews, and oppositions),

Assignor conveys to the Assignee the right to make applications in Assignee's own behalf for protection of the invention in the U.S. and countries foreign to the U.S. and to claim priority to the referenced patent application and other such applications that may be filed in the U.S. or any country foreign to the U.S. on the invention under the Patent Cooperation Treaty, the Paris Convention, and any other international arrangements,

Assignor will not execute any writing or do any act conflicting with the terms of this assignment,

Assignor will at any time upon request, without further or additional consideration, but at the expense of the Assignee, execute such additional assignments and other writings and do such additional acts as the Assignee may deem necessary or desirable to pursue the patent applications identified herein, including, but not limited to, rendering all necessary assistance in making applications for and obtaining patents that may issue thereon in the U.S. and any countries foreign to the U.S. on the invention, and in enforcing any rights accruing as a result of such applications or patents, by, for example, executing statements and other affidavits,

Assignor and Assignee agree the terms of this assignment shall bind, and inure to the benefit of, the legal representatives, successors, and assigns of all parties hereto,

Assignor authorizes Assignee to insert in this assignment the number and filing date of the application if the number and filing date of the application are not recited herein at the time of execution of this assignment by any or all of the parties hereto,

Assignor and Assignee agree that U.S. law governs this assignment, and

Assignee acknowledges and accepts this assignment.

IN WITNESS WHEREOF, Assignor has hereunder set his/her hand on the date shown below.

Date	
	Assignor: Atsushi KUWAHARA
Date	
	Witness:
Date	
L'acc	Witness:

Page 2 of 3

Date	
	Assignor: Suguru YAMASAKI
Date	Witness:
<b>.</b>	
Date	Witness:
Date	Assignor: Miyuki SASAI
	Legal Representative of the Deceased Yoshiki SASAI
Date	Witness:
Date	
	Witness:
Date Sep. 28. 2018	Assignor: Masayo TAKAHASHI
Date Sep. 28, 2018	Cliho Tokutake
	Witness: Miho TOKUTAKE
DateSep . 28 . 2018	Risa Takeuchi Witness: Risa TAKEUCHI
	risa Incuvit

Leydig, Voit & Mayer

**RECORDED: 11/19/2018** 

Page 3 of 3
PATENT

PATENT REEL: 047541 FRAME: 0668